This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boo, L. M. Articles by Ann, D. K. Search for Related Content PubMed PubMed Citation Articles by Boo, L. M. Articles by Ann, D. K.

High Mobility Group A2 Potentiates Genotoxic Stress in Part through the Modulation of Basal and DNA Damage–Dependent Phosphatidylinositol 3-Kinase–Related Protein Kinase Activation

Departments of ¹ Molecular Pharmacology and Toxicology, ² Medicine, and ³ Pharmacy, and ⁴ Norris Cancer Center, University of Southern California, Los Angeles, California; ⁵ Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, California; and ⁶ Department of Pediatrics, University of Rochester, Rochester, New York

Requests for reprints: David K. Ann, University of Southern California, Health Science Campus, PSC-209, 1985 Zonal Avenue, Los Angeles, CA 90033-1049. Phone: 323-442-3409; Fax: 323-224-7473; E-mail: ann{at}usc.edu.

The high mobility group A2 (HMGA2) protein belongs to the architectural transcription factor HMGA family, playing a role in chromosomal organization and transcriptional regulation. We and others have previously reported that ectopic HMGA2 expression is associated with neoplastic transformation and anchorage-independent cell proliferation. Here, we reported a correlation between increased HMGA2 expression and enhanced chemosensitivity towards topoisomerase II inhibitor, doxorubicin, in breast cancer cells. Using cells exhibiting differential HMGA2 expression and small interfering RNA technique, we showed that HMGA2 expression modulates cellular response to the genotoxicity of DNA double-strand breaks. Notably, HMGA2 enhances doxorubicin-elicited cell cycle delay in sub-G₁ and G₂-M and augments cell cycle dysregulation on cotreatment of doxorubicin and caffeine. We further reported that HMGA2 induces a persistent Ser139 phosphorylation of histone 2A variant X, analogous to the activation by doxorubicin-mediated genotoxic stress. Moreover, this HMGA2-dependent enhancement of cytotoxicity is further extended to other double-strand breaks elicited by cisplatin and X-ray irradiation and is not restricted to one cell type. Together, we postulated that the enhanced cytotoxicity by double-strand breaks in HMGA2-expressing cells is mediated, at least in part, through the signaling pathway of which the physiologic function is to maintain genome integrity. These findings should contribute to a greater understanding of the role of HMGA2 in promoting tumorigenesis and conveying (chemo)sensitivity towards doxorubicin and other related double-strand breaks.

This article has been cited by other articles:

				H. Summer, O. Li, Q. Bao, L. Zhan, S. Peter, P. Sathiyanathan, D. Henderson, T. Klonisch, S. D. Goodman, and P. Droge HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy Nucleic Acids Res., May 21, 2009; (2009) gkp375v1. [Abstract] [Full Text] [PDF]

				X. Cao, C. Clavijo, X. Li, H. H. Lin, Y. Chen, H.-M. Shih, and D. K. Ann SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome Mol. Cancer Ther., April 1, 2008; 7(4): 923 - 934. [Abstract] [Full Text] [PDF]

				J. E. Adair, S. C. Maloney, G. A. Dement, K. J. Wertzler, M. J. Smerdon, and R. Reeves High-Mobility Group A1 Proteins Inhibit Expression of Nucleotide Excision Repair Factor Xeroderma Pigmentosum Group A Cancer Res., July 1, 2007; 67(13): 6044 - 6052. [Abstract] [Full Text] [PDF]